ADVFN ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

BMK Benchmark Holdings Plc

24.70
0.00 (0.00%)
18 Jul 2025 - Closed
Share Name Share Symbol Market Type Share ISIN Share Description
Benchmark Holdings Plc LSE:BMK London Ordinary Share GB00BGHPT808 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 24.70 54,509 16:35:15
Bid Price Offer Price High Price Low Price Open Price
24.60 24.80 24.60 24.60 24.60
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 147.73M -39.46M -0.0533 -4.62 182.86M
Last Trade Time Trade Type Trade Size Trade Price Currency
15:42:01 O 4 24.604 GBX

Benchmark (BMK) Latest News

Benchmark (BMK) Discussions and Chat

Benchmark Forums and Chat

Date Time Title Posts
16/6/202519:10Benchmark Holdings Plc545
19/5/202108:35SALMON prices 30 year high and CAT VACCINES are Go-Go566

Add a New Thread

Benchmark (BMK) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type

Benchmark (BMK) Top Chat Posts

Top Posts
Posted at 19/7/2025 09:20 by Benchmark Daily Update
Benchmark Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker BMK. The last closing price for Benchmark was 24.70p.
Benchmark currently has 740,336,243 shares in issue. The market capitalisation of Benchmark is £182,122,716.
Benchmark has a price to earnings ratio (PE ratio) of -4.62.
This morning BMK shares opened at 24.60p
Posted at 16/6/2025 19:10 by edmonda
H1 25 results, proposed delisting from LSE AIM, Investor Presentation video recording

Research note:

For the half year to 31 March 2025, Benchmark Holdings reported revenue from continuing operations (post disposal of the Genetics business area) of £40.6m, -22%YoY (-17% CER), primarily resulting from the pause in sea-based sales of Ectosan®Vet and CleanTreat® in the Health business area. The Group recorded an operating loss of £8.4m (H1 24, £7.2m loss), and (adj.) EBITDA of £4.2m, down 56%YoY.

On 23 May, the Group announced its intention to cancel its Admission to trading on AIM and Euronext Oslo, subject to approval from shareholders and the Norwegian regulator. As part of the process, CEO Trond Williksen will step down from the Board and CFO Septima Maguire will resign.

The planned disposal of the Genetics business was completed on 31 March, realising gross proceeds of £194.0m, from which the Group repaid the outstanding green bond, RCF and hedging instruments to the value of £87m, leaving net cash reserves of £117m.

It is proposed to return c.£95m to shareholder via: (i) a c.£56.7m tender offer for up to 226,934,325 Ordinary Shares at 25.0p/share, and (ii) a special dividend, conditional on the outcome of the General Meeting on 18 June. The rationale for de-listing from AIM includes implied annual cost savings totalling an estimated £8.0m (specific AIM-related, £2.4m, and arising from streamlined operations, £5.6m), and reduced management, legal and regulatory responsibilities.

In light of the decision to de-list subject to shareholder ratification, we have suspended our Fair Value.

Link to note:


Video recording - Investor Presentation:

Trond Williksen (CEO) and Septima Maguire (CFO) of Benchmark Holdings plc (AIM: BMK, Euronext Growth Oslo: BMK), the aquaculture biotechnology business, hosted an Investor Presentation covering Interim numbers for the six month period ended 31 March.

Highlights included the completion of the sale of the Genetics business, resulting in Group profit after tax of £76m, with the continuing business performing in line with expectations. Management discussed the repayment of their Green bond, RCF and related hedging instruments for a total of c. £87m post period end. The team also discussed the recently announced proposals to delist the Company from AIM and Euronext Growth Oslo, and the opportunity for shareholders to roll over into the private company and receive a special dividend. There was a detailed financial overview and a Q&A session where management answered investor queries.

The full presentation is available to watch, divided into chapters as below:
0:00:03 Introduction & Agenda
0:00:50 Highlights
0:06:32 Operational Update
0:12:04 Financial Update
0:19:44 Outlook
0:22:20 Q&A

Link to video:
Posted at 12/6/2025 19:30 by mikeh30
It's an easy win for the market makers. Hold the bid 3% under offer price. Punters get bored and sell up and lose that 3%. MMs bank it.
Posted at 09/6/2025 08:43 by controlledmadness
Does anyone think that the vote will not pass? The share price seems to say that it will not as 25p is a guarantee so why would you sell for less. They said they had 70 percent tied up and only need another 5 percent.
Posted at 01/4/2025 08:48 by jaf111
This is certainly turning out to be a fiasco….far from “unlocking significant shareholder value” the share price has gone from just under 40p to just over 20p!!!!!
And the £260m now far exceed the current mkt cap (£170m)
And the sold business accounted for only around 1/3rd of turnover…̷0;..
Posted at 31/3/2025 16:42 by controlledmadness
So if they distribute it all it will be 14.5 pence per share. But I expect it will be about 5p and the rest for the business.
Posted at 27/3/2025 20:14 by onlymeee
Nonsense, stop scaremongering to get a better price.

Should be valued closer to 50p when the sale concludes
Posted at 10/1/2025 14:21 by controlledmadness
Put in money terms the equity prediction is about 17p being returned per share in 2025.
Is the market saying that the share price has taken this into account or that the resulting company after the 17 p return mat have a 10p a share value?
Posted at 10/1/2025 10:35 by edmonda
"FY24 results: refocus post disposal" - new research (link below)

Benchmark Holdings reported FY24 revenue from continuing operations of £90.4m, -13%YoY (currency adjusted, CER, -6%YoY), and (adj.) EBITDA of £11.9m, -30%YoY (CER: -24%YoY reflecting the decline in revenue in the Health business (-57%YoY) and changes in Advanced Nutrition product mix. Net debt was reduced from £65.5m in FY23 to £49.0m due to the impact of the discontinued Genetics business removing debt related to the Saltern facility. The focus is now on the structure of operations post sale of the Genetics business area, streamlining the organisation and reducing costs.

Post-divestment our revenue and (adj.) EBITDA outlook is determined principally by two factors: trends in the overall market for shrimp (demand and prices), and contribution from the Health business based on Salmosan®Vet revenue streams, in FY25 respectively £86.7m and £12.7m, and for FY26, £90.9m and £14.0m. We reinstate our fair value at 43p/share, to be reviewed on completion of the disposal process as details of the use of proceeds, structure of the balance sheet and proposals for further restructuring emerge. Our revised Fair Value, based on a 5-year DCF, is inclusive of a return of capital to shareholders which we estimate at £158m, to be paid in FY25 (£128m) and FY27 (£30m).

Link to note:
Posted at 10/1/2025 10:18 by jaf111
Can anyone help explain recent weakness in share price….is there a problem with the Novo sale?
Market cap approx £200m which is substantially below the £260m due from Genetics sale.
Clearly I must be missing something…..
Posted at 07/8/2024 13:33 by edmonda
Save the Date! 22nd August - Q3 Results Investor Presentation - sign up below!

Benchmark Holdings plc (AIM: BMK, Euronext Growth Oslo: BMK), the aquaculture biotechnology business, will be conducting an investor presentation following publication of their Q3 results for the nine month period ended 30 June 2024.

The online event will be hosted by Trond Williksen, CEO, and Septima Maguire, CFO, and will take place on Thursday 22nd August at 12.00pm (UK time).

The webinar is open to all existing and potential shareholders. Questions can be submitted during the presentation to be addressed at the end.

Link to register here:
Benchmark share price data is direct from the London Stock Exchange

Benchmark Frequently Asked Questions (FAQ)

What is the current Benchmark share price?
The current share price of Benchmark is 24.70p
How many Benchmark shares are in issue?
Benchmark has 740,336,243 shares in issue
What is the market cap of Benchmark?
The market capitalisation of Benchmark is GBP 182.86M
What is the 1 year trading range for Benchmark share price?
Benchmark has traded in the range of 16.50p to 43.00p during the past year
What is the PE ratio of Benchmark?
The price to earnings ratio of Benchmark is -4.62
What is the cash to sales ratio of Benchmark?
The cash to sales ratio of Benchmark is 1.23
What is the reporting currency for Benchmark?
Benchmark reports financial results in GBP
What is the latest annual turnover for Benchmark?
The latest annual turnover of Benchmark is GBP 147.73M
What is the latest annual profit for Benchmark?
The latest annual profit of Benchmark is GBP -39.46M
What is the registered address of Benchmark?
The registered address for Benchmark is BENCHMARK HOUSE, 8 SMITHY WOOD DRIVE, SHEFFIELD, S35 1QN
What is the Benchmark website address?
The website address for Benchmark is benchmarkplc.com
Which industry sector does Benchmark operate in?
Benchmark operates in the PHARMACEUTICAL PREPARATIONS sector

Your Recent History

Delayed Upgrade Clock